Jill Feldman: Inclusion rate of QOL metrics and PROs in clinical trials
Jill Feldman, Co-Founder of EGFR Resisters, shared a post by Mara Antonoff, Associate Professor Thoracic and Cardiovascular Surgery at MD Anderson Cancer Center, on X:
“Thank you, Cecilia Pompili, for highlighting the disappointingly and unacceptably low inclusion rate of QOL metrics and PROs in clinical trials. My question is, Why? Could it be a lack of understanding or education about their importance and how to use them in trials? Instead of going on about the low rate of use, how can we educate investigators (esp early in their careers) so they are in a position to succeed? ”
Quoting Mara Antonoff‘s post:
“Inclusion of quality-of-life metrics and patient-reported outcomes in lung cancer clinical trials is disappointingly and unacceptably low, as highlighted by Dr Cecilia Pompili at ELIXR24.”
Source: Jill Feldman/X and Mara Antonoff/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023